Hydroxychloroquine: a comprehensive analysis from pharmacological mechanism to clinical application

First paragraph: Summary of content
Hydroxychloroquine (HCQ) is an anti-malarial and immunomodulatory drug widely used to treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Its core mechanisms include inhibiting immune cell activity and interfering with lysosomal function, but attention should be paid to its potential side effects such as retinal toxicity. The main content is divided into four parts: pharmacological effects, indications, medication precautions and manufacturers, focusing on its scientific application and risk balance.

Paragraph 2: Pharmacological effects and indications
Hydroxychloroquine exerts an immunomodulatory effect by inhibiting the Toll-like receptor signaling pathway and reducing the release of inflammatory factors. It can also change the pH value of lysosomes to interfere with antigen presentation. In addition to anti-malaria,FDA approvedIndications include rheumatoid arthritis, discoid lupus erythematosus, etc. Its potential antiviral effect caused controversy during the 2020 COVID-19 epidemic, but subsequent studies did not confirm significant efficacy (New England Journal of Medicine, 2020).

Paragraph 3: Medication Precautions
Long-term use of hydroxychloroquine requires regular monitoring of the risk of retinopathy, and eye examinations are recommended every 6 months. Common side effects also include gastrointestinal reactions and rash. Contraindications include those allergic to 4-aminoquinoline drugs and patients with severe hepatic insufficiency. American College of Rheumatology (ACR) guidelines emphasizeIndividualized dose adjustment, the basic dose is usually 5 mg/kg/day (ACR Guidelines, 2022).

Paragraph 4: Manufacturer and product
The original drug of hydroxychloroquine is produced by Sanofi under the trade namePlaquenil. Common domestic generic drug manufacturers include Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., Fu'an Pharmaceutical Co., Ltd., etc. The following table lists the main production information:

Paragraph 5: Summary and Outlook
As a classic immunomodulator, hydroxychloroquine’s efficacy and safety must strictly follow clinical guidelines. Future studies may explore its use in other autoimmune diseases, but the benefits and risks need to be balanced. Patients should follow the doctor's advice when taking medication and avoid adjusting the dosage on their own.

Citing sources
1. "New England Journal of Medicine": Study on the efficacy of hydroxychloroquine in COVID-19 (2020)
2. American College of Rheumatology (ACR): Hydroxychloroquine Medication Guidelines (2022)
3. Production information: Sanofi official website, State Food and Drug Administration database